Adaptimmune, PCT in Supply Pact
By

By
Adaptimmune Therapeutics, an Oxfordshire, UK-based T-cell therapy company, has formed a new five-year strategic manufacturing agreement with PCT, a contract manufacturing organization and a Caladrius company, a subsidiary of Caladrius…

Johnson Matthey Facility Passes MHRA Inspection
By

By
Johnson Matthey, a provider of pharmaceutical services, active pharmaceutical ingredients and catalyst technologies, has received GMP approval for its facilities in Annan, UK, following a program of renovation and refitment.…

Almac Group Invests $5.2 Million to Expand in North Carolina
By

By
Almac Group, a contract development and manufacturing organization headquartered in Craigavon, UK, has plans to invest $5.2 million in and create almost 80 new jobs across its facilities in Durham,…

Cambrex to Acquire PharmaCore for $25 Million
By

By
Cambrex has agreed to acquire PharmaCore, a High Point, North Carolina-based company specializing in developing and manufacturing small-molecule active pharmaceutical ingredients (APIs), for approximately $25 million.  PharmaCore develops and produces…

Particle Sciences, Glenmark Partner
By

By
Glenmark Pharmaceuticals, headquartered in Mumbai, India, has entered into a strategic development, license, and commercialization agreement with Particle Sciences, a Bethlehem, Pennsylvania-based contract development and manufacturing organization and part of…

Pfizer Completes $14 Billion Acquisition of Medivation
By

By
Pfizer has completed its previously announced $14 billion acquisition of Medivation, a San Francisco-based biopharmaceutical company, following completion of the antitrust review under the Hart-Scott-Rodino Antitrust Improvements Act of 1976,…

Eleven Biotherapeutics Acquires Viventia Bio
By

By
Eleven Biotherapeutics, a Cambridge, Massachusetts-based clinical-stage pharmaceutical company developing anti-cancer agents, has acquired Viventia Bio, Winnipeg, Canada-based biopharmaceutical company. Under the agreement, Eleven purchased all of the outstanding capital stock…

Antitrust Period Ends for Pfizer’$14 Billion Acquisition of Medivation
By

By
Pfizer has moved closer to closing its $14-billion acquisition of Medivation, a San Francisco-based biopharmaceutical company with the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended.…

Pfizer Decides To Keep Company As One; No Spinoffs in Future
By

By
Pfizer has announced that the company will not pursue separating the company into two independent companies, one focused on the company’s innovator products and the second on the company’s established products business.The company…

Ligand Licenses Programs to Seelos Therapeutics
By

By
Ligand Pharmaceuticals, a San Diego-based biopharmaceutical company, has licensed the rights to four programs to Seelos Therapeutics, a newly formed New York-based biopharmaceutical company focused on central nervous system (CNS),…